THU0694 BRAZILIAN SJÖGREN’S SYNDROME REGISTRY (BRASS): A LARGE BRAZILIAN MULTICENTRIC COHORT OF PRIMARY SJÖGREN’S SYNDROME
Authors: Valeria Valim, Samira Tatiyama Miyamoto, Maria Lúcia Lemos Lopes, Aysa Cesar Pinheiro, Aysa Cesar Pinheiro, Leandro Augusto Tanure, Fabiola Reis Oliveira, Vanessa Hax, Aiessa Zanchett Fedrigo, Henrique Pereira Sampaio, Roberta de Almeida Pernambuco, Érica Vieira Serrano, Sabrina Zanardi Machado, Virginia Fernandes Moça Trevisan
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Primary Sjögren’s syndrome (pSS) is an orphan systemic autoimmune disease with no treatment based on evidence<sup>1</sup>. There is an international effort for multicentric registries for getting information about phenotypes, complication, response of treatment, and biobank consortium. <h3>Objectives</h3> To describe the creation of the Brazilian Sjögren’s Syndrome Registry (BRASS) and present the preliminary data. <h3>Methods</h3> BRASS is supported by Brazilian Society of Rheumatology (SBR) and is including patients from all regions of the country. Recruitment started in 2018 and is due to be completed in 2024. We are including patients with pSS according to AECG 2002 or ACR-EULAR 2016 classification criteria. All patients are being assessed for disease activity (ESSDAI), disease damage (SSDDI), symptoms assessment (ESSPRI), fatigue (FACIT-Fatigue), anxiety and depression (HADS), sleepiness (Epworth Sleepiness Scale), physical activity (IPAQ-SF) and quality of life (EQ-5D). In addition, demographics, immunological tests, unstimulated whole salivary flow (UWSF), salivary gland biopsy (SGB), comorbidities, treatment and complications such as cancer and cardiovascular risk assessment are being collected. <h3>Results</h3> There are currently 10 centers across the Brazil and 248 patients were evaluated until now. Most patients were female, white (45%) or mixed (38.3%), with the mean of the disease duration of 8 years. ESSDAI at baseline was 6.62±6.37 and currently is 4.21±5.16 (p&lt;0.05). The mean of the SSDDI was 2.16±1.60 and ESSPRI 8.38±6.88. SGB was positive in 81.5% and focus score mean was 1.58±1.30. Schirmer test I was positive in 72.6%, van Bijsterveld in 70.9% and UWSF in 84.8%. About classification criteria, 91.9% fulfilled AECG 2002 and 94% ACR/EULAR 2016. Anti-Ro and anti-La were positive in 70.8% and 35.5%, respectively. Forty three percent had positive RF, 88.5% ANA, 6.9% low C3, 10.2% low C4, 34.9% high IgG. Nineteen percent were using prednisone, 40.4% immunosuppressant, 53.6% antimalarial and 17.6% biological therapy. Prevalence of cardiovascular event was 7.5%, hypertension 43.3%, diabetes 13.3%, dyslipidemia 31.5%, smoking 5.8% and cancer 7.5%. <h3>Conclusion</h3> ESSDAI has decreased over time and more than half of patients are on hydroxychloroquine, immunosuppressant or biological therapy. Further analysis is needed to understand whether the reduction in ESSDAI reflects the natural course of the disease or greater access to treatment. BRASS Registry will be important to enhance research and to develop public health planning. <h3>References</h3> [1] Valim V et al. Recommendations for the treatment of Sjögren’s syndrome. Rev Bras Reumatol 55:446–57, 2015. <h3>Disclosure of Interests</h3> None declared